A Phase 2 interventional study of Apixaban and Apixaban in Acute Coronary Syndrome, sponsored by Pfizer. Terminated at 18 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-08-29.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Acute Coronary Syndrome with a site in Japan — 4 open to participants now, 7 under way, 1 of them phase 3. Acute Coronary Syndrome · Japan.
Among the 33 studies in Acute Coronary Syndrome with a site in Japan, this one is the 23rd largest by enrollment of the 25 interventional ones that give a count, is one of 6 that started in 2009, is one of 3 in phase 2, and was the 7th registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.
Browse Acute Coronary Syndrome studies →4 of the 33 studies in Acute Coronary Syndrome with a site in Japan are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Japan, Argentina, Australia and 11 more countries
Ages 18+
Stephen Nicholls · Sites in Japan, Australia, China and 6 more countries
Ages 18+
Fujita Health University · Sites in Japan
Ages 20+
Kitasato University · Sites in Japan
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 6 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 151 is below the median of 200 across 868 interventional studies indexed under Acute Coronary Syndrome.
Median enrollment 2,000 across the 25 interventional studies, 527 across the 8 observational. Of the 26 that completed or were terminated, 12 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 33 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 2 studies filed under Acute Coronary Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Acute Coronary Syndrome with a site in Japan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07102628Phase 3Novartis PharmaceuticalsEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | 2027-02-11 |
| NCT05325034Stephen NichollsGuideline Oriented Approach To Lipid Lowering In Asia-Pacific | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 33 studies in Acute Coronary Syndrome with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the bleeding safety (the composite endpoint of major and clinically relevant non-major bleeding) of 2 doses of apixaban (2.5 mg BID and 5.0 mg BID) or placebo in combination with standard therapy (aspirin and /or additional antiplatelet therapy) over a 24 week treatment period in selected subjects with recent (≤7 days) acute coronary syndrome.
Due to withdraw of global phase 3 study (APPRAISE-2) for safety issue, B0661004 Data monitoring committee (DMC) also recommended terminating this study. Therefore, Pfizer decided to stop this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Apixaban
Drug: Apixaban
Other: Placebo
Percentage of Participants Who Had Composite of International Society on Thrombosis and Haemostasis (ISTH)-Defined Major and Clinically-relevant Non-major (CRNM) Bleeding Events Occurring During the Treatment Period.
Major bleeding event was acute clinically overt bleeding accompanied by decrease in hemoglobin of 2 g/dL or more over a 24-hour period, transfusion of 2 or more units of packed red blood cells, or bleeding that occurs in critical site (e.g., intracranial). Fatal bleeding was also major bleeding event. CRNM bleeding was acute or sub-acute clinically overt bleeding that did not satisfy the criteria for major bleeding and that led to either hospital admission for bleeding, physician guided medical or surgical treatment for bleeding or a change in antithrombotic therapy.
Time frame: Week 0 to Week 24
Percentage of Participants Who Had One or More All Bleeding Occurring During the Treatment Period.
All bleeding included major bleeding (including fatal bleeding), clinically-relevant non-major (CRNM) bleeding, and minor bleeding per international society on thrombosis and haemostasis (ISTH) definitions.
Time frame: Week 0 to Week 24
Percentage of Participants Who Had Major Bleeding Occurring During the Treatment Period Per International Society on Thrombosis and Haemostasis (ISTH) Definitions.
Major bleeding event was defined as an acute clinically overt bleeding accompanied by decrease in hemoglobin of 2 g/dL or more over a 24-hour period, transfusion of 2 or more units of packed red blood cells, or bleeding that occured in critical site (e.g., intracranial). Fatal bleeding was also major bleeding event.
Time frame: Week 0 to Week 24
Percentage of Participants Who Had Thrombolysis in Myocardial Infarction (TIMI)-Defined Major Bleeding Occurring During the Treatment Period.
TIMI major bleeding event was difined as an intracranial bleeding or clinically overt bleeding (including bleeding evident on imaging studies) associated with a \>= 5 gm/dL fall in hemoglobin or a 15% fall in hematocrit from baseline, accounting for the effect of transfusions (1 unit packed red blood cells = 1 gm/dL hemoglobin = 3% hematocrit).
Time frame: Week 0 to Week 24
Percentage of Participants Who Had Composite of All-cause Death, Non-fatal Myocardial Infarction, Unstable Angina and Stroke During 30 Days After Discontinuation of Therapy.
Time frame: For 30 days after Week 24 or the discontinuation of study drug
Percentage of Participants Who Had Composite of All-cause Death, Non-fatal Myocardial Infarction (MI), Unstable Angina, and Non-hemorrhagic Stroke Occurring During the Intended Treatment Period.
Intended treatment period for efficacy endpoints was defined as a period starting on the day of randomization and ending at the later date of either 2-days after the last dose of study drug or Day 168/Week 24 after randomization day (or the study termination date \[19 November 2010, Japan time\]).
Time frame: From the day of randomization to the later date of either 2-days after the last dose of study drug or Day 168/Week 24 after randomization day (or the study termination date [19 November 2010, Japan time])
Percentage of Participants Who Had International Society on Thrombosis and Haemostasis (ISTH)-Defined Individual Bleeding Endpoints (Clinically-relevant Non-major [CRNM] or Minor Bleeding) During the Treatment Period.
ISTH-defined CRNM bleeding was defined as an acute or sub-acute clinically overt bleeding that did not satisfy the criteria for major bleeding and that led to either hospital admission for bleeding, physician guided medical or surgical treatment for bleeding or a change in antithrombotic therapy. ISTH defined minor bleeding event was defined as all acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM bleeding were classified as minor bleeding.
Time frame: Week 0 to Week 24
Percentage of Participants Who Had Thrombolysis in Myocardial Infarction (TIMI) Defined-individual Bleeding Endpoints (Minor or Minimal Bleeding) During the Treatment Period.
TIMI minor bleeding event was defined as a clinically overt bleeding (including bleeding evident on imaging studies) associated with a \>= 3 gm/dL fall in hemoglobin or a 9% fall in hematocrit from baseline, accounting for the effect of transfusions (1 unit packed red blood cells = 1 gm/dL hemoglobin = 3% hematocrit). TIMI minimal bleeding event was defined as a clinically overt bleeding (including bleeding evident on imaging studies) not meeting criteria for TIMI minor bleeding.
Time frame: Week 0 to Week 24
| Milestone | Placebo | Apixaban 2.5 mg BID | Apixaban 5.0 mg BID |
|---|---|---|---|
| Started | 52 | 49 | 50 |
| Treated participants | 51 | 49 | 49 |
| Completed | 41 | 41 | 36 |
| Not completed | 11 | 8 | 14 |
| Withdrew: Adverse event | 4 | 6 | 4 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 4 | 1 | 2 |
| Withdrew: Study terminated by sponsor | 2 | 1 | 6 |
| Withdrew: Difficulty in study site visit | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
Major bleeding event was acute clinically overt bleeding accompanied by decrease in hemoglobin of 2 g/dL or more over a 24-hour period, transfusion of 2 or more units of packed red blood cells, or bleeding that occurs in critical site (e.g., intracranial). Fatal bleeding was also major bleeding event. CRNM bleeding was acute or sub-acute clinically overt bleeding that did not satisfy the criteria for major bleeding and that led to either hospital admission for bleeding, physician guided medical or surgical treatment for bleeding or a change in antithrombotic therapy.
| Percentage of Participants | Placebo | Apixaban 2.5 mg BID | Apixaban 5.0 mg BID |
|---|---|---|---|
| Percentage of Participants Who Had Composite of International Society on Thrombosis and Haemostasis (ISTH)-Defined Major and Clinically-relevant Non-major (CRNM) Bleeding Events Occurring During the Treatment Period. | 2.0 (0.10 to 9.82) | 4.1 (0.73 to 13.34) | 4.1 (0.73 to 13.34) |
All bleeding included major bleeding (including fatal bleeding), clinically-relevant non-major (CRNM) bleeding, and minor bleeding per international society on thrombosis and haemostasis (ISTH) definitions.
| Percentage of Participants | Placebo | Apixaban 2.5 mg BID | Apixaban 5.0 mg BID |
|---|---|---|---|
| Percentage of Participants Who Had One or More All Bleeding Occurring During the Treatment Period. | 33.3 (20.76 to 47.23) | 38.8 (26.01 to 53.76) | 44.9 (30.83 to 59.77) |
Major bleeding event was defined as an acute clinically overt bleeding accompanied by decrease in hemoglobin of 2 g/dL or more over a 24-hour period, transfusion of 2 or more units of packed red blood cells, or bleeding that occured in critical site (e.g., intracranial). Fatal bleeding was also major bleeding event.
| Percentage of Participants | Placebo | Apixaban 2.5 mg BID | Apixaban 5.0 mg BID |
|---|---|---|---|
| Percentage of Participants Who Had Major Bleeding Occurring During the Treatment Period Per International Society on Thrombosis and Haemostasis (ISTH) Definitions. | 0 (0.00 to 6.31) | 2.0 (0.10 to 10.24) | 4.1 (0.73 to 13.34) |
TIMI major bleeding event was difined as an intracranial bleeding or clinically overt bleeding (including bleeding evident on imaging studies) associated with a \>= 5 gm/dL fall in hemoglobin or a 15% fall in hematocrit from baseline, accounting for the effect of transfusions (1 unit packed red blood cells = 1 gm/dL hemoglobin = 3% hematocrit).
| Percentage of Participants | Placebo | Apixaban 2.5 mg BID | Apixaban 5.0 mg BID |
|---|---|---|---|
| Percentage of Participants Who Had Thrombolysis in Myocardial Infarction (TIMI)-Defined Major Bleeding Occurring During the Treatment Period. | 0 (0.00 to 6.31) | 2.0 (0.10 to 10.24) | 2.0 (0.10 to 10.24) |
| Percentage of Participants | Placebo | Apixaban 2.5 mg BID | Apixaban 5.0 mg BID |
|---|---|---|---|
| Percentage of Participants Who Had Composite of All-cause Death, Non-fatal Myocardial Infarction, Unstable Angina and Stroke During 30 Days After Discontinuation of Therapy. | 0 (0.00 to 6.31) | 0 (0.00 to 6.53) | 2 (0.10 to 10.24) |
Intended treatment period for efficacy endpoints was defined as a period starting on the day of randomization and ending at the later date of either 2-days after the last dose of study drug or Day 168/Week 24 after randomization day (or the study termination date \[19 November 2010, Japan time\]).
| Percentage of Participants | Placebo | Apixaban 2.5 mg BID | Apixaban 5.0 mg BID |
|---|---|---|---|
| Percentage of Participants Who Had Composite of All-cause Death, Non-fatal Myocardial Infarction (MI), Unstable Angina, and Non-hemorrhagic Stroke Occurring During the Intended Treatment Period. | 1.9 (0.10 to 9.63) | 0 (0.00 to 6.53) | 2.0 (0.10 to 10.03) |
ISTH-defined CRNM bleeding was defined as an acute or sub-acute clinically overt bleeding that did not satisfy the criteria for major bleeding and that led to either hospital admission for bleeding, physician guided medical or surgical treatment for bleeding or a change in antithrombotic therapy. ISTH defined minor bleeding event was defined as all acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM bleeding were classified as minor bleeding.
| Percentage of Participants | Placebo | Apixaban 2.5 mg BID | Apixaban 5.0 mg BID |
|---|---|---|---|
| ISTH defined CRNM | 2.0 (0.10 to 9.82) | 2.0 (0.10 to 10.24) | 0 (0.00 to 6.53) |
| ISTH defined minor bleeding | 31.4 (19.63 to 45.07) | 36.7 (23.64 to 51.64) | 40.8 (27.00 to 55.79) |
TIMI minor bleeding event was defined as a clinically overt bleeding (including bleeding evident on imaging studies) associated with a \>= 3 gm/dL fall in hemoglobin or a 9% fall in hematocrit from baseline, accounting for the effect of transfusions (1 unit packed red blood cells = 1 gm/dL hemoglobin = 3% hematocrit). TIMI minimal bleeding event was defined as a clinically overt bleeding (including bleeding evident on imaging studies) not meeting criteria for TIMI minor bleeding.
| Percentage of Participants | Placebo | Apixaban 2.5 mg BID | Apixaban 5.0 mg BID |
|---|---|---|---|
| TIMI defined minor bleeding | 0 (0.00 to 6.31) | 2.0 (0.00 to 6.53) | 2.0 (0.10 to 10.24) |
| TIMI defined minimal bleeding | 33.3 (20.76 to 47.23) | 38.8 (26.01 to 53.76) | 40.8 (27.00 to 55.79) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 8/51 (15.7%) | 22/51 (43.1%) |
| Apixaban 2.5 mg BID | — | 11/49 (22.4%) | 28/49 (57.1%) |
| Apixaban 5.0 mg BID | — | 7/49 (14.3%) | 22/49 (44.9%) |
| Event | Placebo | Apixaban 2.5 mg BID | Apixaban 5.0 mg BID |
|---|---|---|---|
| Coronary artery restenosisInjury, poisoning and procedural complications | 1/51 | 2/49 | 1/49 |
| Angina pectorisCardiac disorders | 1/51 | 0/49 | 1/49 |
| Angina unstableCardiac disorders | 1/51 | 1/49 | 1/49 |
| Arteriospasm coronaryCardiac disorders | 0/51 | 0/49 | 1/49 |
| Coronary artery occlusionCardiac disorders | 0/51 | 1/49 | 0/49 |
| CataractEye disorders | 0/51 | 1/49 | 0/49 |
| PterygiumEye disorders | 0/51 | 0/49 | 1/49 |
| Diverticulum intestinal haemorrhagicGastrointestinal disorders | 0/51 | 0/49 | 1/49 |
| Lower gastrointestinal haemorrhageGastrointestinal disorders | 0/51 | 1/49 | 0/49 |
| Oesophageal ulcerGastrointestinal disorders | 0/51 | 0/49 | 1/49 |
| Event | Placebo | Apixaban 2.5 mg BID | Apixaban 5.0 mg BID |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 4/51 | 4/49 | 8/49 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 6/51 | 6/49 | 4/49 |
| Haemorrhage subcutaneousSkin and subcutaneous tissue disorders | 4/51 | 5/49 | 6/49 |
| Chest discomfortGeneral disorders | 4/51 | 1/49 | 4/49 |
| Blood urine presentInvestigations | 0/51 | 2/49 | 4/49 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/51 | 4/49 | 1/49 |
| HeadacheNervous system disorders | 4/51 | 3/49 | 1/49 |
| DiarrhoeaGastrointestinal disorders | 1/51 | 0/49 | 3/49 |
| Gingival bleedingGastrointestinal disorders | 0/51 | 2/49 | 3/49 |
| FallInjury, poisoning and procedural complications | 0/51 | 3/49 | 2/49 |
| Age Continuous(years) | Placebo | Apixaban 2.5 mg BID | Apixaban 5.0 mg BID | Total |
|---|---|---|---|---|
| Mean | 63.9 ± 10.1 | 66.0 ± 9.0 | 64.0 ± 9.2 | 64.6 ± 9.5 |
| Sex: Female, Male(Participants) | Placebo | Apixaban 2.5 mg BID | Apixaban 5.0 mg BID | Total |
|---|---|---|---|---|
| Female | 10 | 6 | 4 | 20 |
| Male | 42 | 43 | 46 | 131 |
The record gives a start of Apr 2009, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apixaban